Sunshine Guojian Pharmaceutical: Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on a certain website, and the final payment remains uncertain
Sunshine Guojian Pharmaceutical announced that the company has signed an exclusive development, production, and commercialization licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody product 707. The agreement will take effect on July 24, 2025, and Pfizer has registered two global Phase III clinical trials on ClinicalTrials.gov. However, due to milestone payments being subject to specific conditions, there is uncertainty regarding the final payment, and investors should be aware of the risks
According to the Zhitong Finance APP, Sunshine Guojian Pharmaceutical (688336.SH) announced a stock price fluctuation, stating that the company, along with Sunshine Pharmaceutical and Shenyang Sunshine, has jointly granted Pfizer exclusive rights to develop, produce, and commercialize the licensed product 707 project (a bispecific antibody product targeting both PD-1 and VEGF) in the licensed area and field (i.e., all therapeutic, diagnostic, and preventive indications for human and veterinary use). All payments made by the licensee to the licensor will be distributed between the company and Shenyang Sunshine. The "License Agreement" will officially take effect on July 24, 2025.
On October 30, 2025, Pfizer registered two global Phase III clinical trials for the PD-1/VEGF bispecific antibody PF-08634404 (SSGJ-707) on the ClinicalTrials.gov website. Given that the milestone payments stipulated in the "License Agreement" must meet a series of specific conditions, the final payment remains uncertain, and investors are advised to pay attention to investment risks
